News Release

The iSelect Technology Now Supports Custom Designed Panels Ranging from 3,000 to 200,000 SNPs

SAN DIEGO--(BUSINESS WIRE)--Jan. 13, 2009--Illumina, Inc. (NASDAQ:ILMN) today launched the Infinium(R) HD (High
Density) iSelect Custom Genotyping solution. Researchers now have the
flexibility to screen SNPs ranging from 3,000 to 200,000 in focused
genotyping studies for both human and non-human species. This
higher-density iSelect Custom Genotyping technology is the most
versatile solution of its kind in the industry. It offers high data
quality, high-throughput capabilities, and flexible sample multiplexing
to screen any SNP in any species.

The first commercially available products made with the Infinium HD
iSelect technology include the OvineSNP50 and PorcineSNP60 BeadChips.
These 12-sample SNP genotyping products add to Illumina's expanding
agriculture portfolio, helping researchers detect genome-wide genetic
variation in any breed of pig or sheep. The new panels were developed in
collaboration with leading researchers at international consortia and
utilized Illumina's Genome Analyzer, public databases, and other marker
discovery approaches for content selection. Illumina now offers five
standard products for agricultural research: BovineSNP50, EquineSNP50,
CanineSNP20, PorcineSNP60, and OvineSNP50 BeadChips.

AgResearch New Zealand scientist John McEwan, Ph.D., who was involved in
the sequencing and SNP discovery component of the OvineSNP50 BeadChip
development, was impressed with the new ovine array. "We have produced a
high-quality product that exceeds our expectations. The challenge now is
to improve farmed sheep productivity and disease resistance using the
OvineSNP50 BeadChip. Working with Illumina's FastTrack Genotyping
Services, we've genotyped close to three thousand samples with the
OvineSNP50 BeadChip and we plan to genotype at least the same number of
samples every year hereafter."

At this week's Plant and Animal Genome (PAG) conference in San Diego,
California, scientists from major agricultural research institutions,
including Martien Groenen, Ph.D., Professor of the Animal Breeding and
Genetics Group at Wageningen University, and Brian P. Dalrymple, Ph.D.,
of the Australian Commonwealth Scientific and Industrial Research
Organization (CSIRO) Livestock Industries, on behalf of the
International Sheep Genomics Consortium, will present overviews of their
work developing custom genotyping panels with Illumina.

"Researchers from a wide range of markets work with Illumina because
iSelect is the only custom whole-genome genotyping technology optimized
for use with both human and non-human samples," said Joel McComb, Senior
Vice President and General Manager of Illumina's Life Sciences Business
Unit. "By deploying the Infinium HD assay on the iSelect platform
customers have access to more than three times the number of SNPs per
sample than on our previously designed iSelect panels."

The expansion of the Illumina iSelect offering provides researchers more
freedom to design custom panels from the large amount of human variant
information generated by research programs, such as the 1,000 Genomes
Project. Agricultural researchers will be able to create more effective
genotyping panels for complex or less well understood genomes.

Illumina (www.illumina.com)
is a leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the analysis of genetic
variation and biological function. Using our proprietary technologies,
we provide a comprehensive line of products and services that currently
serve the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers
include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world
with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract
valuable medical information from advances in genomics and proteomics.
We believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: this release may contain forward-looking statements that
involve risks and uncertainties. Among the important factors that could
cause actual results to differ materially from those in any
forward-looking statements are Illumina's ability (i) to develop and
commercialize further our BeadArray(TM), VeraCode(R), and Solexa(R)
technologies and to deploy new sequencing, gene expression, and
genotyping products and applications for our technology platforms, (ii)
to manufacture robust instrumentation and reagents technology, together
with other factors detailed in our filings with the Securities and
Exchange Commission including our recent filings on Forms 10-K and 10-Q
or in information disclosed in public conference calls, the date and
time of which are released beforehand. We disclaim any intent or
obligation to update these forward-looking statements beyond the date of
this release.